National Vision (EYE)
(Delayed Data from NSDQ)
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
National Vision (EYE) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.
National Vision (EYE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 750% and 4.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to National Vision (EYE) for Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).
Cardiovascular Systems (CSII) Business Down on COVID Resurgence
by Zacks Equity Research
According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.
Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida
by Zacks Equity Research
Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.
National Vision (EYE) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 52.00% and 0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.
Here's Why You Should Hold on to Hill-Rom (HRC) for Now
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Walgreens (WBA) to Make Additional Investment in VillageMD
by Zacks Equity Research
Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.
National Vision (EYE) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
by Riya Anand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.